The cardiovascular portfolio
Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes Eliquis, one of the company’s largest selling products. The chart below shows Eliquis revenue over the last few quarters.
Eliquis is a drug approved for the prevention of venous thromboembolism disorders and the prevention of stroke in patients with non-valvular atrial fibrillation. The drug is developed in collaboration with Pfizer (PFE).
Eliquis recorded revenue of $1.2 billion in 3Q17, ~39% growth from the $884 million seen in 3Q16. In 3Q17, Eliquis recorded sales of $717 million from US markets, a ~40% rise from 3Q16’s $512 million.
Both US and international sales rose due to strong demand for the drug. As the drug is approved for a large number of indications, it’s often prescribed. However, despite the increase in Eliquis sales, the drug contributes less to profit margin improvement as its cost of sales is higher than that of Bristol-Myers Squibb’s other products.
The company is also developing new drugs for unmet needs in cardiovascular diseases such as arrhythmia, atherosclerosis, atrial fibrillation, heart failure, and thrombosis. Notably, the iShares Morningstar Large-Cap Growth ETF (JKE) has a 14.7% exposure to healthcare companies. JKE has a 1.5% exposure to Bristol-Myers Squibb, a 1.2% exposure to Celgene (CELG), a 0.8% exposure to Allergan (AGN), and a 0.7% exposure to Stryker (SYK).